In conclusion, systemic administration of either CXCL9-Fc or CXCL10-Fc markedly increases the relative number of activated highly potent tumor-specific CD8+ T cells at the tumor site, and to some extent PD-1 expression on about 7-10% of these cells. Here, CXCL9 is linked to neoplasm.